title: Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports.
abstract: A 42-year-old woman with liver metastasis from adrenal cortical carcinoma was treated with mitotane (o,p'DDD) for 11 months with a minimal response. Mitotane was stopped because of severe adverse effects. Thereafter a combination of cisplatin and etoposide was given every 3 weeks. A partial response was achieved after five chemotherapy courses. Following this chemotherapy, the patient had a surgical excision of the liver metastasis and entered into a complete remission for 17 months. Etoposide plus cisplatin may be an active combination for the treatment of adrenal cortical carcinoma.
authors.affiliation: Northern Israel Oncology Center, Rambam Medical Center, Endocrinology Unit, Bnei-Zion Hospital, Haifa, Israel.
authors.forename: J
authors.initials: J
authors.lastname: Zidan
authors.forename: M
authors.initials: M
authors.lastname: Shpendler
authors.forename: E
authors.initials: E
authors.lastname: Robinson
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000473:pathology*; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D008939:Mitotane / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D005047:Etoposide; D008939:Mitotane; D002945:Cisplatin